<DOC>
	<DOCNO>NCT02587832</DOCNO>
	<brief_summary>To compare primary outcome , failure extubation define need re-intubation mechanical ventilation within 5 day initial extubation secondary outcome , morbidity mortality use heat humidity high flow nasal cannula ( HHHFNC ) Nasal Continuous Positive Airway Pressure ( NCPAP ) immediate post-extubation period preterm infant 24 28 week gestation respiratory distress syndrome .</brief_summary>
	<brief_title>High Flow Nasal Cannula Comparison With Nasal Continuous Positive Airway Pressure Management Respiratory Distress Syndrome</brief_title>
	<detailed_description>Inclusion criterion : 1 ) Preterm neonates gestational age 24 28 complete week . 2 ) In case twin , neonate include treatment arm . 3 ) Success wean 24 hour extubate . 4 ) Parental write informed consent participation study obtain admission hospital prior delivery . Exclusion criterion : 1 ) Evidence severe birth asphyxia . 2 ) Known genetic chromosomal disorder . 3 ) Infants deliver mother rupture membrane three week duration . 4 ) Potentially life-threatening condition unrelated prematurity . 5 ) Participation another clinical trial placebo , drug , biological , device conduct provision protocol . Randomization A computer-generated block-randomization sequence random block size use . Infants part multiple births underwent individual randomization . Clinicians open consecutively number , seal , brown envelope immediately extubation determine study-group assignment .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<criteria>1 . Preterm neonates gestational age 24 28 complete week . 2 . In case twin , neonate include treatment arm . 3 . Success wean 24 hour extubate . 4 . Parental write informed consent participation study obtain admission hospital prior delivery . 1 . Evidence severe birth asphyxia . 2 . Known genetic chromosomal disorder . 3 . Infants deliver mother rupture membrane three week duration . 4 . Potentially lifethreatening condition unrelated prematurity . 5 . Participation another clinical trial placebo , drug , biological , device conduct provision protocol .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>cpap</keyword>
	<keyword>HHHFNC</keyword>
	<keyword>RDS</keyword>
	<keyword>ELBW</keyword>
</DOC>